2024-11-15T08:23:12-06:00 2023-12-31 263753134 CBIZ ADVISORS LLC 500 BOYLSTON STREET BOSTON MA 02116 990 2023-01-01 461681862 MICROBIOME HEALTH RESEARCH INSTITUTE INC MICR 6175752201 400 WEST CUMMINGS PARK PMB 203 17 WOBURN MA 018016579 JULIE BARRETT O'BRIEN CHIEF EXECUTIVE OFFICER 6175752201 2024-11-14 1 1 BRENDA L BOOTH P01342395 6177610600 2024-11-14 2023 2024-10-15 13:58:12Z OPENBIOME JULIE BARRETT O'BRIEN 400 WEST CUMMINGS PARK PMB 203 1725 WOBURN MA 018016579 8434737 0 X WWW.OPENBIOME.ORG X 2013 MA OPENBIOME IS A PIONEERING NONPROFIT THAT ACCELERATES BOLD DISCOVERIES IN MICROBIOME SCIENCE, ETHICALLY AND EQUITABLY, TO IMPROVE HEALTH FOR ALL. 9 9 23 9 0 0 926050 785396 112610 22100 162602 309412 913602 3259140 2114864 4376048 0 0 0 0 2112206 2320669 0 0 0 1357971 1189107 3470177 3509776 -1355313 866272 9439432 9964560 1597953 1232036 7841479 8732524 X OPENBIOME IS A PIONEERING NONPROFIT THAT ACCELERATES BOLD DISCOVERIES IN MICROBIOME SCIENCE, ETHICALLY AND EQUITABLY, TO IMPROVE HEALTH FOR ALL. 0 0 1390228 3233441 ALIGNED WITH CURRENT FDA POLICY, OPENBIOME REMAINS COMMITTED TO ENSURING THAT ALL PATIENTS SUFFERING FROM C. DIFFICILE INFECTION CONTINUE TO HAVE SAFE, CONVENIENT, AND AFFORDABLE ACCESS TO FECAL MICROBIOTA TRANSPLANTATION (FMT) THROUGH THEIR PHYSICIAN. IN OUR COLLABORATION WITH THE UNIVERSITY OF MINNESOTA (UMN), UNDER AN ACTIVE INVESTIGATIONAL DRUG APPLICATION (IND), WE CONTINUE TO DISTRIBUTE FMT TO OUR CLINICAL NETWORK AND ARE WORKING WITH FDA TO ENSURE THAT ALL REGULATORY FILINGS ARE KEPT CURRENT AND COMPLIANT WITH THE EXISTING POLICY AND GUIDANCE. WE STRIVE TO MAKE THE PATH TO TREATMENT AS SIMPLE AS POSSIBLE FOR PATIENTS AND THEIR DOCTORS, WHILE BRINGING A LEVEL OF SAFETY AND STANDARDIZATION TO THE PROCESS THAT HAS SET THE STANDARD FOR THIS EMERGING FIELD. OPENBIOME PROVIDES FMT THAT HAS BEEN MANUFACTURED BY UMN AND HAS BEEN RIGOROUSLY SCREENED. THESE READY-TO-USE FECAL MICROBIOTA PREPARATIONS ALLOW PHYSICIANS TO DEVOTE THEIR TIME AND ENERGY TO TREATING PATIENTS, RATHER THAN THE COMPLEXITIES OF MANAGING A STOOL DONOR PROGRAM. 39484 22100 CLINICAL RESEARCH PROGRAM: OPENBIOME SEEKS TO ENABLE TRANSLATIONAL RESEARCH ON THE HUMAN MICROBIOME. TO DO SO, WE PROVIDE A SUITE OF SERVICES TO HELP INVESTIGATORS UNCOVER THE ROLE OF THE GUT MICROBIOME IN HUMAN HEALTH, AND TO DISCOVER HOW ENGINEERING IT CAN DRIVE BETTER HEALTH OUTCOMES. OUR SERVICES INCLUDE THE PROVISION OF CUSTOMIZED FECAL MICROBIOTA PREPARATIONS, STUDY DESIGN AND REGULATORY SUPPORT FOR CLINICAL TRIALS, AND BIOINFORMATICS AND ANALYTICAL SERVICES. OPENBIOME ALSO SPONSORS ITS OWN STUDIES INVESTIGATING CRITICAL MICROBIOME-RELATED HEALTH CONDITIONS. 897620 25699 THE GLOBAL MICROBIOME CONSERVANCY (GMBC) PROGRAM AT OPENBIOME PARTNERS WITH SCIENTISTS AROUND THE WORLD TO CONSERVE, STUDY, AND SHARE UNDERREPRESENTED AND AT-RISK HUMAN MICROBIOME DIVERSITY. THE GMBC HAS ESTABLISHED A NETWORK OF 80+ RESEARCHERS IN OVER THREE DOZEN COUNTRIES AND BUILT A DIVERSE COLLECTION OF SAMPLES AND BACTERIAL ISOLATES TO SPARK SCIENTIFIC DISCOVERY AND ENABLE NEW SOLUTIONS TO MICROBIOME-ASSOCIATED DISEASE.THE GMBC WAS ESTABLISHED TO SOLVE THE URGENT NEED FOR A DEEPER, MORE GLOBALLY REPRESENTATIVE UNDERSTANDING OF THE HUMAN MICROBIOME THAT ADDRESSES THE HEALTH CONCERNS OF ALL. A DEEPER UNDERSTANDING OF THE HUMAN MICROBIOME IS CRITICAL TO SOLVING GLOBAL HEALTH CHALLENGES SUCH AS ANTIMICROBIAL RESISTANCE, MALNUTRITION, DEPRESSION, AS WELL AS AUTOIMMUNE AND METABOLIC DISORDERS THAT ARE LINKED TO THE COMMUNITIES OF BACTERIA THAT LIVE WITHIN US. HOWEVER, OUR CURRENT BODY OF KNOWLEDGE, LARGELY BASED ON U.S. AND EUROPEAN POPULATIONS, IS BIASED AND VASTLY INCOMPLETE. AS INDUSTRIALIZATION DISRUPTS HUMAN MICROBIOME DIVERSITY ON A GLOBAL SCALE, THE WINDOW OF OPPORTUNITY TO STUDY AND APPLY THE FULL POTENTIAL OF THE HUMAN MICROBIOME IS CLOSING.TO RADICALLY EXPAND SCIENTISTS' VIEW OF THE MICROBIOME, THE GMBC PROGRAM HAS BUILT A GLOBALLY REPRESENTATIVE COLLECTION OF HUMAN MICROBIOME SAMPLES, BACTERIAL ISOLATES, AND ASSOCIATED METADATA AS A RESOURCE FOR THE RESEARCH COMMUNITY. WORKING WITH LOCAL SCIENTISTS AROUND THE WORLD, WE COLLECT AND CONSERVE MICROBIOME SAMPLES (PRIMARILY GUT, BUT ALSO MOUTH, SKIN AND OTHER BODY SITES) FROM PARTICIPATING COMMUNITIES. THESE SAMPLES ARE THEN CHARACTERIZED AND, FROM THEM, THE GMBC GENERATES BACTERIAL ISOLATES. RESULTING RESEARCH MATERIALS AND ASSOCIATED DATA ARE SHARED THROUGH THE GMBC COLLECTIONTHE MOST GLOBALLY REPRESENTATIVE COLLECTION OF ITS KIND THAT PROVIDES SCIENTISTS ACCESS TO PREVIOUSLY UNAVAILABLE BIODIVERSITY.IN NOVEMBER 2023, OPENBIOME BEGAN THE TRANSFER OF THE GLOBAL MICROBIOME CONSERVANCY PROGRAM TO KIEL UNIVERSITY. OPENBIOME REMAINS A FUNDER OF THE PROGRAM AND AGREED TO DISTRIBUTE A MAXIMUM OF FOUR (4) GRANTS UP TO $50,000 EACH TO IN-COUNTRY COLLABORATORS IN THE 2024 COLLECTION PIPELINE. 2327332 1 1 0 0 0 0 0 0 0 0 1 1 0 1 1 1 1 0 0 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 26 0 1 23 1 0 0 0 0 0 0 0 0 0 0 0 0 X 9 9 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MA X X PAUL LEECH 6175752201 400 WEST CUMMINGS PARK SUITE 1725 WOBURN MA 018016579 LISA SERWIN DIRECTOR/VICE CHAIR & SECRETARY 10.00 X X 0 0 0 JANE WILLIAMS MD DIRECTOR/TREASURER 2.00 X X 0 0 0 NEIL RASMUSSEN DIRECTOR/BOARD CHAIR 2.00 X X 0 0 0 ERIC ALM PHD DIRECTOR 2.00 X 0 0 0 JAMES BILDNER DIRECTOR 2.00 X 0 0 0 STEPHEN JONES DIRECTOR 2.00 X 0 0 0 JOANNE KAMENS PHD DIRECTOR 2.00 X 0 0 0 RUCHIKA KUMAR DIRECTOR 2.00 X 0 0 0 GARABET YERETSSIAN PHD DIRECTOR 2.00 X 0 0 0 PAUL LEECH CHIEF OPERATING OFFICER 40.00 X 209107 0 16008 KEN LINDE CHIEF INFORMATION OFFICER 40.00 X 197254 0 37650 MAJDI OSMAN MD MPH CHIEF MEDICAL OFFICER 40.00 X 200484 0 16342 JULIE O'BRIEN CHIEF EXECUTIVE OFFICER 40.00 X 231693 0 38093 SUSAN WEIR SENIOR SCIENTIST 40.00 X 137216 0 4162 KATYA MONIZ DIR OF GLOBAL MICROBIOME CONSERVANCY 40.00 X 153158 0 14496 MICHAEL BOUGAS CLINICAL OUTREACH DIRECTOR 40.00 X 135000 0 24366 DAVE MCCALL HUMAN RESOURCES DIRECTOR 40.00 X 141570 0 35595 SHEVON WALKER DIR OF CMC & SUPPLY CHAIN LOGISTICS 40.00 X 150338 0 37246 1555820 0 223958 14 0 1 0 MINTZ 1 FINANCIAL CENTER FLOOR 39 BOSTON MA 02111 LEGAL 100157 1 757338 28058 785396 GENERAL RESEARCH SERVICES 541900 22100 22100 22100 233309 233309 71603 4500 0 0 71603 4500 76103 76103 7317829 4058689 3259140 3259140 4376048 3281240 0 309412 440003 285966 154037 1372428 891965 480463 53869 43507 10362 321253 208788 112465 133116 109210 23906 111037 87165 23872 76705 49852 26853 15510 15510 259048 170300 88748 165372 108375 56997 597 388 209 328596 213560 115036 59341 38567 20774 31049 20179 10870 38414 32135 6279 103013 66950 36063 SUBCONTRACTOR EXPENSES 425 425 3509776 2327332 1182444 0 1299880 2003562 49125 87947 0 406334 1226101 779575 258720 155400 105086 99988 472038 364345 124409 107693 362555 203377 4942156 5360434 1071400 760250 9439432 9964560 597899 530567 1000054 701469 1597953 1232036 X 7841479 8732524 7841479 8732524 9439432 9964560 866272 24773 0 X 0 1 X 1 0 X 396591 377967 1212784 926050 785396 3698788 15114080 9646475 7423251 6500830 7339929 46024565 15510671 10024442 8636035 7426880 8125325 49723353 301854 244000 27560 11919 14029 599362 0 301854 244000 27560 11919 14029 599362 49123991 241570 259796 1348357 161762 233309 2244794 241570 259796 1348357 161762 233309 2244794 15752241 10284238 9984392 7588642 8358634 51968147 0.94530 0.93660 0.04320 0.05090 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 294702 263887 30815 104074 27196 76878 73262 73262 0 107693 CORPORATE BONDS 4622048 F U.S. TREASURIES 517560 F GOVERNMENT BONDS 220826 F 5360434 SECURITY DEPOSIT 196200 RIGHT-OF-USE ASSETS, OPERATING LEASE 564050 760250 OPERATING LEASE OBLIGATION 564050 PAYCHECK PROTECTION PROGRAM LOAN 137419 701469 X 4385311 24773 24773 4360538 15510 15510 4376048 3494266 0 3494266 15510 15510 3509776 PART X, LINE 2: THE ORGANIZATION ACCOUNTS FOR THE EFFECT OF ANY UNCERTAIN TAX POSITIONS BASED ON A "MORE LIKELY THAN NOT" THRESHOLD TO THE RECOGNITION OF THE TAX POSITIONS BEING SUSTAINED BASED ON THE TECHNICAL MERITS OF THE POSITION UNDER SCRUTINY BY THE APPLICABLE TAXING AUTHORITY. IF A TAX POSITION OR POSITIONS ARE DEEMED TO RESULT IN UNCERTAINTIES OF THOSE POSITIONS, THE UNRECOGNIZED TAX BENEFIT IS ESTIMATED BASED ON A "CUMULATIVE PROBABILITY ASSESSMENT" THAT AGGREGATES THE ESTIMATED TAX LIABILITY FOR ALL UNCERTAIN TAX POSITIONS. INTEREST AND PENALTIES ASSESSED, IF ANY, ARE ACCRUED AS INCOME TAX EXPENSE. THE ORGANIZATION HAS IDENTIFIED ITS STATUS AS A TAX EXEMPT ENTITY AS ITS ONLY SIGNIFICANT TAX POSITION AND HAS DETERMINED THAT SUCH TAX POSITION DOES NOT RESULT IN AN UNCERTAINTY REQUIRING RECOGNITION. THE ORGANIZATION IS NOT CURRENTLY UNDER EXAMINATION BY ANY TAXING JURISDICTION. EUROPE (INCLUDING ICELAND & GREENLAND) 0 1 PROGRAM SERVICES MALNUTRITION RESEARCH 216827 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES STRATEGIC BUSINESS ADVISORY SERVICES 82333 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES BIOLOGICAL SAMPLING 45000 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES GMBC PROGRAM 35613 0 1 0 0 0 1 379773 0 379773 0 0 0 0 0 0 X X 0 0 0 0 0 0 0 1 0 JULIE O'BRIEN CHIEF EXECUTIVE OFFICER 200793 0 30900 0 0 0 7100 0 30993 0 269786 0 0 0 KEN LINDE CHIEF INFORMATION OFFICER 170989 0 26265 0 0 0 6035 0 31615 0 234904 0 0 0 PAUL LEECH CHIEF OPERATING OFFICER 181357 0 27750 0 0 0 6382 0 9626 0 225115 0 0 0 MAJDI OSMAN MD MPH CHIEF MEDICAL OFFICER 174219 0 26265 0 0 0 6035 0 10307 0 216826 0 0 0 SHEVON WALKER DIR OF CMC & SUPPLY CHAIN LOGISTICS 130060 0 20278 0 0 0 4660 0 32586 0 187584 0 0 0 DAVE MCCALL HUMAN RESOURCES DIRECTOR 122437 0 19133 0 0 0 4396 0 31199 0 177165 0 0 0 KATYA MONIZ DIR OF GLOBAL MICROBIOME CONSERVANCY 133073 0 20085 0 0 0 4615 0 9881 0 167654 0 0 0 MICHAEL BOUGAS CLINICAL OUTREACH DIRECTOR 117189 0 17811 0 0 0 4093 0 20273 0 159366 0 0 0 PART I, LINE 3 MEMBERS OF THE BOARD OF DIRECTORS MUST APPROVE OFFICER COMPENSATION. THIS COMPENSATION IS REVIEWED ANNUALLY AGAINST INDUSTRY AND MARKET COMPARABLES. COMPENSATION IS SET BY INDEPENDENT PERSONS AND DOCUMENTED CONTEMPORANEOUSLY. PART I, LINE 7 THE BOARD REVIEWS THE FINANCIALS AND HAS THE OPTION EACH YEAR TO DECLARE SOME OR NO BONUSES. IF THE BOARD DECIDES TO GIVE A BONUS, AN OVERALL PERCENTAGE IS RECOMMENDED. A STAFF LIST IS THEN DEVELOPED BASED ON THE RECOMMENDATION AND REVIEWED BY TOP LEADERSHIP, WHERE PERFORMANCE BASED ADJUSTMENTS MAY BE MADE. FORM 990, PART VI, SECTION B, LINE 11B COPIES OF THE COMPLETED DRAFT FORM 990 (INCLUDING REQUIRED SCHEDULES) ARE DISTRIBUTED TO THE BOARD MEMBERS BY EITHER ELECTRONIC OR PAPER FORM FOR REVIEW AND APPROVAL. ANY QUESTIONS OR CONCERNS WILL BE NOTED AND ADDRESSED, AND MANAGEMENT STAFF WILL ENSURE THAT CHANGES ARE INCORPORATED INTO THE FORM 990 AS APPROPRIATE. AFTER ALL INPUT HAS BEEN APPROPRIATELY ADDRESSED, THE FINAL VERSION OF THE FORM 990 (WITH REQUIRED SCHEDULES) WILL BE DISTRIBUTED TO EVERY VOTING MEMBER OF THE ORGANIZATION'S BOARD OF DIRECTORS PRIOR TO FILING WITH THE IRS. THE FINAL FORM MAY BE DISTRIBUTED EITHER IN PAPER OR ELECTRONIC FORM IN ANY MANNER DEEMED APPROPRIATE BY THE ORGANIZATION'S CHIEF OPERATING OFFICER. FORM 990, PART VI, SECTION B, LINE 12C ALL STAFF, OFFICERS, AND DIRECTORS ARE REQUIRED TO SIGN THE CONFLICT OF INTEREST POLICY AND DISCLOSE ANY POTENTIAL OR PERCEIVED CONFLICTS TO MANAGEMENT. ANY CONFLICTS OF INTEREST DISCLOSED ARE DISCUSSED BY THE BOARD OF DIRECTORS AND MANAGEMENT. FORM 990, PART VI, SECTION B, LINE 15 MEMBERS OF THE BOARD OF DIRECTORS MUST APPROVE OFFICER COMPENSATION. THIS COMPENSATION IS REVIEWED ANNUALLY AGAINST INDUSTRY AND MARKET COMPARABLES. COMPENSATION IS SET BY INDEPENDENT PERSONS AND DOCUMENTED CONTEMPORANEOUSLY. FORM 990, PART VI, SECTION C, LINE 19 FORM 990S AND ANNUAL AUDITED FINANCIAL STATEMENTS ARE POSTED ON THE COMPANY WEBSITE, WWW.OPENBIOME.ORG, AS WELL AS GUIDESTAR.ORG.